Evolution of acute myelogenous leukemia stem cell properties after treatment and progressionTzu‐Chieh Ho, Michael W. Becker, Mark W. LaMere et al.|Blood|2016Cited by 236
<i>DNMT3A</i> Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous LeukemiaAlison R. Sehgal, Martin Carroll, Alison W. Loren et al.|Clinical Cancer Research|2015Cited by 55
ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?Jingmei Hsu, Selina M. Luger, Elizabeth O. Hexner et al.|Blood|2014Cited by 0